BNP Measurement Reduces Resource Utilization for Patients With CHF Admitted Thorough the ED

Completed

Conditions studied: Congestive Heart Failure

In brief

Measurement of brain natriuretic peptide (BNP) in dyspneic patients increases diagnostic accuracy for congestive heart failure (CHF). Limited information is available regarding economic outcomes attributable to BNP assay. The aim of this study was to assess the economic impact of BNP assay in elderly dyspneic patients presenting to the emergency department (ED).

Key facts

Study ID

NCT00587938

Run by

Mayo Clinic

People needed

200

Starts

2003-12-01

Expected to finish

2005-03-01

Last updated by the study team

2008-01-08

Who can join

Age: 65 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Dyspneic patients 65 years or older presenting to the ED with chief complaint of shortness of breath.

You may not qualify if…

• hemodynamically unstability

Where it is running

• Saint Marys Hospital, Mayo Clinic — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.